Enzymatica AB (publ) (ENZY.ST)
SEK 1.68
(-1.18%)
SEK 1.68
(-1.18%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -0.28 SEK | 31.82% |
| 2022 | -0.44 SEK | -41.94% |
| 2021 | -0.31 SEK | -235.14% |
| 2020 | -0.09 SEK | 68.1% |
| 2019 | -0.29 SEK | 35.56% |
| 2018 | -0.45 SEK | -28.57% |
| 2017 | -0.35 SEK | 48.53% |
| 2016 | -0.68 SEK | 52.78% |
| 2015 | -1.44 SEK | -15.2% |
| 2014 | -1.25 SEK | -58.23% |
| 2013 | -0.79 SEK | -92.68% |
| 2012 | -0.41 SEK | -5.13% |
| 2011 | -0.39 SEK | 0.0% |
| 2009 | -0.01 SEK | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q1 | -0.11 SEK | -28.5% |
| 2024 Q2 | -0.07 SEK | 27.73% |
| 2023 Q3 | -0.06 SEK | 19.83% |
| 2023 Q4 | -0.09 SEK | -52.31% |
| 2023 FY | - SEK | 31.82% |
| 2023 Q1 | -0.09 SEK | 35.14% |
| 2023 Q2 | -0.07 SEK | 22.8% |
| 2022 Q3 | -0.08 SEK | 15.3% |
| 2022 Q4 | -0.14 SEK | -65.29% |
| 2022 FY | - SEK | -41.94% |
| 2022 Q1 | -0.12 SEK | -63.49% |
| 2022 Q2 | -0.10 SEK | 16.67% |
| 2021 Q2 | -0.14 SEK | -125.81% |
| 2021 Q4 | -0.07 SEK | -79.46% |
| 2021 FY | - SEK | -235.14% |
| 2021 Q1 | -0.06 SEK | -2718.18% |
| 2021 Q3 | -0.04 SEK | 70.79% |
| 2020 Q1 | 0.01 SEK | 126.81% |
| 2020 Q4 | -0.00 SEK | 83.46% |
| 2020 Q3 | -0.01 SEK | 83.78% |
| 2020 Q2 | -0.08 SEK | -920.0% |
| 2020 FY | - SEK | 68.1% |
| 2019 FY | - SEK | 35.56% |
| 2019 Q4 | -0.04 SEK | 31.18% |
| 2019 Q2 | -0.11 SEK | -28.65% |
| 2019 Q1 | -0.09 SEK | -10.61% |
| 2019 Q3 | -0.05 SEK | 50.73% |
| 2018 Q4 | -0.08 SEK | 29.73% |
| 2018 FY | - SEK | -28.57% |
| 2018 Q3 | -0.11 SEK | 35.29% |
| 2018 Q2 | -0.17 SEK | -54.55% |
| 2018 Q1 | -0.11 SEK | -78.57% |
| 2017 FY | - SEK | 48.53% |
| 2017 Q4 | -0.06 SEK | -61.68% |
| 2017 Q1 | -0.12 SEK | 36.84% |
| 2017 Q2 | -0.12 SEK | 0.0% |
| 2017 Q3 | -0.04 SEK | 68.25% |
| 2016 Q2 | -0.19 SEK | 34.48% |
| 2016 Q3 | -0.08 SEK | 57.95% |
| 2016 Q4 | -0.19 SEK | -137.8% |
| 2016 Q1 | -0.29 SEK | 27.5% |
| 2016 FY | - SEK | 52.78% |
| 2015 Q3 | -0.40 SEK | -8.11% |
| 2015 FY | - SEK | -15.2% |
| 2015 Q4 | -0.40 SEK | 0.0% |
| 2015 Q1 | -0.32 SEK | 31.91% |
| 2015 Q2 | -0.37 SEK | -15.63% |
| 2014 Q4 | -0.47 SEK | -113.64% |
| 2014 Q1 | -0.30 SEK | -30.43% |
| 2014 Q3 | -0.22 SEK | 24.14% |
| 2014 Q2 | -0.29 SEK | 3.33% |
| 2014 FY | - SEK | -58.23% |
| 2013 Q2 | -0.17 SEK | -30.77% |
| 2013 Q4 | -0.23 SEK | 11.54% |
| 2013 FY | - SEK | -92.68% |
| 2013 Q3 | -0.26 SEK | -52.94% |
| 2013 Q1 | -0.13 SEK | -18.18% |
| 2012 FY | - SEK | -5.13% |
| 2012 Q3 | -0.04 SEK | 83.95% |
| 2012 Q2 | -0.22 SEK | -100.0% |
| 2012 Q1 | -0.11 SEK | 0.0% |
| 2012 Q4 | -0.11 SEK | -211.61% |
| 2011 Q2 | -0.11 SEK | 0.0% |
| 2011 FY | - SEK | 0.0% |
| 2011 Q3 | -0.09 SEK | 19.82% |
| 2011 Q1 | - SEK | 0.0% |
| 2010 Q2 | -0.01 SEK | 0.0% |
| 2010 Q3 | -0.09 SEK | -1002.5% |
| 2009 FY | - SEK | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| AcuCort AB | -0.16 SEK | -75.0% |
| AlzeCure Pharma AB (publ) | -0.60 SEK | 53.333% |
| BioGaia AB (publ) | 3.62 SEK | 107.735% |
| Enorama Pharma AB (publ) | -1.61 SEK | 82.609% |
| Gabather AB (publ) | -0.65 SEK | 56.923% |
| Klaria Pharma Holding AB (publ.) | -0.36 SEK | 22.222% |
| Moberg Pharma AB (publ) | -1.33 SEK | 78.947% |
| Nanexa AB (publ) | -1.09 SEK | 74.312% |
| Newbury Pharmaceuticals AB (publ) | -0.72 SEK | 61.111% |
| ODI Pharma AB | 0.02 SEK | 1296.581% |
| Orexo AB (publ) | -3.73 SEK | 92.493% |
| Probi AB (publ) | 1.48 SEK | 118.919% |
| Swedencare AB (publ) | 0.37 SEK | 175.676% |
| Swedish Orphan Biovitrum AB (publ) | 7.47 SEK | 103.748% |
| Toleranzia AB | -0.06 SEK | -400.0% |
| Vivesto AB | -0.74 SEK | 62.162% |